艾迪药业2025年净利亏损1973.37万元 同比减亏

Core Viewpoint - Aidi Pharmaceutical reported a significant increase in revenue for the fiscal year 2025, driven by the growth in sales of its innovative anti-HIV drugs and the consolidation of Nanda Pharmaceutical's operational data [1] Group 1: Financial Performance - The company achieved an operating revenue of 721 million yuan, representing a year-on-year growth of 72.49% [1] - The net profit attributable to the company was a loss of 19.73 million yuan, indicating a reduction in losses compared to the previous year [1] Group 2: Factors Influencing Performance - The increase in gross profit from core business operations was approximately 25.5 million yuan compared to the same period last year, attributed to higher revenues from anti-HIV innovative drugs and the consolidation of Nanda Pharmaceutical [1] - Sales expenses increased by about 9.2 million yuan year-on-year due to intensified promotion efforts for new drugs and the inclusion of Nanda Pharmaceutical's operational data [1] - Asset impairment losses decreased by approximately 4.8 million yuan year-on-year, as market expansion and expectations stabilized [1]